Serbia

Serbia - a land of opportunity for clinical research.

Over the years, Serbia has become a highly reputable place to conduct clinical research. The country has actively strived towards developing a robust healthcare system and has adopted a full GCP compliance. An increasing number of biotechnology and pharmaceutical companies are now willing to envision Serbia as a potential regional hub for their business operations and thus make significant investments in the Serbian market.

Serbia Country Profile

Serbia – a land of opportunity for clinical research

29 Nov 2022

The past, the present, and the future When someone mentions Serbia in a scientific context, the name of Nicola Tesla inevitably comes to mind. But very few people know that Serbia has produced some of the truly great minds in medicine. One such scientist is Miodrag Radulovacki, who is considered to be the father...

United States

With a population of over 330 million, a well-developed medical infrastructure, an ethnically diverse patient population, and the largest concentration of biotechnology and pharma companies, the United States remains an unequivocal leader and trendsetter in clinical research. Therefore, it is not surprising that half of the world’s clinical trials are conducted in the United States. In addition to the agile regulatory framework with fast initiation timelines, world-leading scientific minds, and high-quality clinical trial data, inclusion of US clinical sites is essential for drug registration with the FDA. Cromos Pharma has a strong track record of conducting clinical research in the US since 2018. Additionally, the company has a unique advantage of offering a balanced approach of including both US and ex-US clinical sites that helps accelerate recruitment and saves time and resources.

Bulgaria

Bulgaria ranks top 20 in the world in clinical trials performed and offers great potential for pharmaceutical companies and contract research organizations. Bulgaria is considered one of Europe’s clinical research hubs. Around 190 new studies are started every year in the country with approximately 12,000 patients annually enrolled. Bulgarian Association of Clinical Research (BACR) is advocating for high standard in conducting clinical trials and adherence to the requirements of the international standards.

Croatia

Croatia provides a natural conduit between EU and non-EU countries, providing an advantage of the Croatian language which is easily understood by the non-EU countries surrounding it. Croatia has a rich heritage in terms of science and good experience in clinical research conduct. As a result many contract research organizations chose Croatia for clinical trials conduct.

Czech Republic

The Czech Republic is a well-established location for clinical trials conduct with a strong track record of generating high quality clinical trials data. In recent years, it has developed a reputation as an attractive location for niche clinical trials including hematologic malignancies, gene and cell therapies, and rare diseases. Cromos Pharma began its operations in the Czech Republic in 2010 and established a representative office in Prague in 2015.

Estonia

The healthcare sector in Estonia is rapidly developing. The government of Estonia is constantly working to improve the clinical research environment in the country. The number of study centers has grown and the annual number of submitted clinical trial protocols have steadily increased over the last two decades. .

Georgia

Georgia offers international sponsors significant benefits that include a rapid regulatory approval process, substantial naïve patient populations in a wide range of therapeutic indications, skilled medical personnel, and a conducive economic environment for doing business. Cromos Pharma began conducting clinical research in Georgia in 2013. Since then, our Tbilisi-based operation has grown exponentially, managing numerous successful regional and global studies in a broad range of therapeutic indications.

Hungary

Hungary boasts several key advantages for sponsors considering this country as a destination for their clinical research. Its membership in the EU, high educational standards, recent launch of national programs aimed at developing a strong medical research sector, and general economic initiatives aimed at attracting international investment all position Hungary as an attractive location. Each year approximately 20,000 Hungarian patients participate in clinical trials. Cromos Pharma established its office in Budapest in 2016.

Kazakhstan

There are many benefits to conducting clinical research in Kazakhstan, its strategic geography being one of them. Kazakhstan is a transcontinental country located between Europe and Central Asia, and it’s health demographics draw influence from both continents. This is one reason why an increasing number of biopharmaceutical companies are considering Kazakhstan as a venue for conducting its clinical research. Cromos Pharma began operations in Kazakhstan in 2017, where it initially conducted phase 3 oncology trials, but since has broadened its scope of services. The company opened a regional office in Almaty in 2021.

Latvia

There is a stable increase in clinical trials in Latvia over the last 10 years. GCP trainings are well organized by the Medicine Information Centre and most of the investigators are GCP trained. Following the European Union accession, Latvia has implemented EU directives 2001/20 and 2005/28, and incorporated GCP guidelines into the national law.

Lithuania

Lithuania offers companies a business model favorable to the conduct of clinical research, which is increasingly recognized by many key players in the sector. More than 90 international biotech, pharma and medical companies, including global ones, have chosen Lithuania as a location to conduct their studies.

Serbia - a land of opportunity for clinical research.

Cromos Pharma’s Services in Serbia:

What we do

Patient recruitment

Clinical Research Services

Regulatory Services

EU legal representation

Medical Writing

Data Management

CTM Logitics

PV Support

Independent Audits

Rare and Orphan Diseases

Belgrade office